07-15-2010, 08:13 AM
Human Genome Sciences, Inc. (Nasdaq:HGSI) and Lonza announced an agreement for the future commercial supply of BENLYSTAŽ (belimumab), which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE)...
07-15-2010, 12:24 PM
In lupus and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies - antibodies that attack and destroy the body's own healthy tissues. The presence of autoantibodies appears to correlate with disease severity. Preclinical and clinical studies demonstrated that belimumab reduced autoantibody levels in SLE. The results of two pivotal Phase 3 trials, BLISS-52 and BLISS-76, demonstrated that belimumab reduced SLE disease activity.